I hope that Neuren will give NNZ-2591 a run at a Phase 2 for Autism - even an announcement to that effect would be a powerful message about the scope and potential of the drug. Good results in the current P2 studies will provide a foundation in the science as to the likelihood that autism is a good indication to pursue.
Ann: Investor Presentation, 14 March 2023, page-42
-
- There are more pages in this discussion • 104 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.47 |
Change
-0.050(0.24%) |
Mkt cap ! $2.606B | |||
| Open | High | Low | Value | Volume |
| $20.60 | $20.77 | $20.32 | $3.274M | 159.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 608 | $21.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.53 | 183 | 1 |
View Market Depth
| Last trade - 15.59pm 15/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |